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Abstract
Background: Community-acquired pneumonia (CAP) is one of the most common infections presenting to the
emergency department (ED). Increasingly, antibiotic resistant bacteria have been identified as causative pathogens
in patients treated for CAP, especially in patients with healthcare exposure risk factors.
Methods: We retrospectively identified adult subjects treated for CAP in the ED requiring hospital admission
(January 2003-December 2011). Inappropriate antibiotic treatment, defined as an antibiotic regimen that lacked
in vitro activity against the isolated pathogen, served as the primary end point. Information regarding demographics,
severity of illness, comorbidities, and antibiotic treatment was recorded. Logistic regression was used to determine
factors independently associated with inappropriate treatment.
Results: The initial cohort included 259 patients, 72 (27.8%) receiving inappropriate antibiotic treatment. There was no
difference in hospital mortality between patients receiving inappropriate and appropriate treatment (8.3% vs. 7.0%;
p = 0.702). Hospital length of stay (10.3 ± 12.0 days vs. 7.0 ± 8.9 days; p = 0.017) and 30-day readmission (23.6% vs.
12.3%; p = 0.024) were greater among patients receiving inappropriate treatment. Three variables were independently
associated with inappropriate treatment: admission from long-term care (AOR, 9.05; 95% CI, 3.93-20.84), antibiotic
exposure in the previous 30 days (AOR, 1.85; 95% CI, 1.35-2.52), and chronic obstructive pulmonary disease (AOR, 2.05;
95% CI, 1.52-2.78).
Conclusion: Inappropriate antibiotic treatment of presumed CAP in the ED negatively impacts patient outcome and
readmission rate. Knowledge of risk factors associated with inappropriate antibiotic treatment of presumed CAP could
advance the management of patients with pneumonia presenting to the ED and potentially improve patient outcomes.
Keywords: Pneumonia, Antibiotics, Resistant pathogens, Outcomes
Background
Community-acquired pneumonia (CAP) is an important
infection globally, and accounts for significant morbidity,
mortality, and economic burden [1-5]. Mortality may be
as high as 14% overall, whereas for the elderly, mortality
reaches greater than 50% within 5 years [1,5]. Treatment
of CAP is potentially compromised by the rapid emer-
gence of bacterial resistance to the most commonly
prescribed antibiotics, including beta-lactams, macro-
lides, and fluoroquinolones [6]. Even multidrug-resistant
(MDR) strains (commonly defined as resistance to three
or more of the commonly used classes of agents) are
emerging [6]. Traditionally, pneumonia developing in
recently hospitalized patients or those residing in long-
term care facilities, nursing homes, or undergoing dialysis,
has been classified and treated as CAP. However, a new
pneumonia classification, distinct from CAP —healthcare-
associated pneumonia (HCAP)—has been introduced to
address patients outside of the hospital at risk of infection
with MDR pathogens [7]. The 2005 American Thoracic
Society/Infectious Disease Society of America (ATS/IDSA)
guidelines also recognized HCAP as a new category of
pneumonia [8].
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Patients with HCAP risk factors are at increased risk
of infection with MDR pathogens [9-16]. Physicians
should be aware that microbiological features and clin-
ical outcomes of patients with HCAP are more similar
to patients with hospital-acquired pneumonia (HAP)
than those with traditional CAP [9]. A critical disparity
appears to be the more frequent administration of in-
appropriate antibiotic treatment in patients with HCAP
compared to those with CAP, secondary to a higher inci-
dence of antibiotic-resistant pathogens in HCAP [13].
However, factors associated with inappropriate antibiotic
administration in the emergency department (ED), and
the short- and long-term impact of inappropriate ther-
apy has not been well studied. Therefore, we performed
an investigation to assess the incidence of inappropriate
initial antibiotic treatment of hospitalized patients with
presumed CAP presenting to the ED. We also aimed to
assess risk factors associated with inappropriate anti-
biotic treatment and its relationship to other clinical
outcomes.
Methods
Study overview and subjects
We retrospectively identified all hospitalized adult
(age >18 years) patients diagnosed and treated for
culture-positive CAP in the ED between January 1,
2003 and December 31, 2011. Presumed CAP was de-
fined as a new or progressive radiographic infiltrate
plus one of the following: temperature greater than
38.3°C, WBC greater than 10,000/μL, or purulent tra-
cheal secretions. One investigator (MHK), blinded to
the clinical and microbiologic information adjudicated
the chest imaging. To be included, patients had to be
treated in the ED with a CAP antimicrobial regimen
that included at our institution ceftriaxone plus azi-
thromycin or moxifloxacin. Identification of pathogens
was based on the results of cultures obtained in the ED
from blood, pleural fluid, sputum, or the lower airways.
A positive urinary antigen for Legionella pneumophilia
serogroup 1 was used to document infection with this
pathogen. The Washington University School of Medicine
Human Studies Committee approved the study.
Endpoints and covariates
Patients receiving inappropriate therapy, defined as an
antibiotic regimen that lacked in vitro activity against
the isolated pathogen, were compared to those receiving
appropriate antibiotic therapy. Covariates of interest
included patient demographics, severity of illness, the
Charlson score, and antibiotic treatment. Demographic
factors included age, gender, and race. Comorbidities po-
tentially influencing the isolated pathogen included resi-
dence in a long-term care facility, hospitalization in the
last 90 days, receipt of antimicrobials in the last 30 days,
end-stage renal disease requiring hemodialysis, and im-
munosuppression. Immunosuppression was defined as the
presence of the human immunodeficiency virus (HIV),
active malignancy undergoing chemotherapy, or treatment
with immunosuppressants (i.e., 10 mg prednisone or
equivalent daily for at least 30 days or alternate agents).
Disease severity was assessed with the CURB-65 score,
along with the need for either intensive care unit (ICU)
admission or mechanical ventilation [17]. Infection-
related variables included the presence of bacteremia
complicating the pneumonia, and the presence of poly-
microbial infection. We classified the initial antibiotic
regimen as appropriate if the antibiotic regimen demon-
strated in vitro activity against the pathogen(s) isolated
and was administered within 6 hours of presentation.
Statistics
We completed univariate analyses with either the Fisher’s
exact test or Student’s t-test as appropriate. Continuous,
non-parametrically distributed data was compared via the
Mann–Whitney U test. All analyses were two tailed, and a
p value of < 0.05 was statistically significant. Logistic regres-
sion was used to determine independent factors associated
with inappropriate treatment. Variables significant at
p < 0.10 in univariate analyses were entered into the model.
To arrive at the most parsimonious model we utilized a
step-wise backward elimination approach. Co-linearity was
explored with correlation matrices. Adjusted odds ratios
(AORs) and ninety-five percent confidence intervals (CIs)
are reported where appropriate. The model’s goodness-of-
fit was assessed via calculation of the R2 value and the
Hosmer-Lemeshow c-statistic. All analyses were performed
with SPSS 11.0 (SPSS, Chicago, IL).
Results
During the study period there were 1367 patients with
culture-positive bacterial pneumonia admitted from the
ED. Among these 1108 (81.5%) were diagnosed and
treated for presumed HCAP, received initial treatment
with broad-spectrum antibiotics and excluded from ana-
lysis. Of the 259 patients diagnosed and treated for CAP,
187 (72.2%) received appropriate antibiotic treatment
and 72 (27.8%) received inappropriate treatment (Figure 1).
Overall hospital mortality was 7.3% and 30-day hospital re-
admission was 15.4%. The average hospital length of stay
was 7.9 days (median 5 days).
Table 1 shows the characteristics of patients receiving
appropriate and inappropriate antibiotic treatment. There
were no differences in demographics or severity of illness
between groups. There was a trend towards greater ICU
admission for patients receiving inappropriate treatment
(p = 0.052).
With respect to infection-related characteristics, pa-
tients receiving appropriate treatment were more likely
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to be infected with Streptococcus pneumoniae, MSSA,
Escherichia coli and Haemophilus influenzae (Table 2).
MRSA, Pseudomonas aeruginosa, Enterobacter species
and Acinetobacter species were more common among
patients receiving inappropriate treatment. MRSA was
the most common pathogen accounting for inappropri-
ate treatment (47.2%) followed by Pseudomonas aerugi-
nosa (27.8%). Tracheal aspirates and bronchoalveolar
lavage specimens were more often used to establish the mi-
crobiologic diagnosis among patients receiving inappropri-
ate treatment. There was no difference in the presence of
polymicrobial infection or secondary bacteremia between
groups.
We observed an association between comorbidities
and inappropriate treatment. The median Charlson score
was higher in patients receiving inappropriate treatment
(5 vs. 4, p = 0.090). Neurologic conditions such as de-
mentia and stroke occurred equally between groups
while other chronic diseases, such as chronic obstructive
pulmonary disease (COPD), chronic kidney disease, and
peripheral vascular disease occurred more often in patients
receiving inappropriate treatment. Of the comorbidities
evaluated, those linked to the definition of HCAP corre-
lated with inappropriate treatment (Table 1). For example,
long-term care patients were more than nine times (OR,
9.96; 95% CI, 2.02-49.18) as likely to receive inappropriate
treatment. Patients on chronic dialysis (OR, 5.58; 95% CI,
1.36-22.93) or having received previous antibiotic treatment
(OR, 2.12; 95% CI, 1.18-3.79) were also significantly more
likely to receive inappropriate treatment.
Overall, 129 (49.8%) patients were retrospectively
found to have at least one HCAP risk factor. Patients
having any of the HCAP risk factors were significantly
less likely to receive appropriate antibiotic treatment
compared to patients with no HCAP risk factors (61.2%
versus 83.1%; p < 0.001). Inappropriate antibiotic treat-
ment was not associated with excess mortality (Table 3).
However, hospital length of stay was significantly lon-
ger among patients receiving inappropriate treatment.
Similarly, 30-day hospital readmission was statistically
greater among patients who initially received inappro-
priate treatment.
The results of the logistic regression analyses are shown
in Tables 4 and 5. Admission from a long-term care facility,
antibiotic exposure in the previous 30 days, and COPD
were independently associated with the administration of
inappropriate treatment. A similar analysis using 30-day
hospital readmission as the dependent outcome identified
three independent risk factors for this outcome: antibiotic
exposure in the previous 30 days, presence of peripheral
vascular disease and increasing CURB-65 scores.
Discussion
This retrospective analysis of patients diagnosed and
treated for CAP in the ED reveals that inappropriate
antibiotic treatment is common and primarily due to
the presence of antibiotic-resistant pathogens includ-
ing MRSA and non-lactose fermenting Gram-negative
bacteria (NLFGNB). We found that almost one half of
the patients treated for CAP in the ED had at least one
risk factor for healthcare-associated infection. Healthcare-
associated risk factors, including prior antibiotic exposure
and long-term care residency, were found to be predictors
for inappropriate antibiotic treatment. Our study is unique
Figure 1 Flow diagram depicting bacterial pneumonia patients admitted from the emergency department. HCAP: healthcare-associated
pneumonia; CAP: community-acquired pneumonia.
Micek et al. BMC Infectious Diseases 2014, 14:61 Page 3 of 8
http://www.biomedcentral.com/1471-2334/14/61
in showing that prior antibiotic exposure, presumably by
predisposing to inappropriate antibiotic treatment, may also
be associated with subsequent 30-day hospital readmission.
These data add to the growing evidence elucidating
the importance of discriminating between patients with
pneumonia having healthcare-associated risk factors, in-
cluding prior antibiotic exposure, from those without
such risk factors. In one of the largest studies examining
the epidemiology of pneumonia, approximately one-
third of all patients with pneumonia admitted to the
hospital were due to HCAP [9]. Subsequent studies have
also documented that HCAP represents between 30%
and 60% of pneumonias requiring hospitalization in the
US [11,14,18,19], and this trend is also observed in Asia
and Europe [10,12,13,20]. Our study also confirms that
MRSA and NLFGNB are common pathogens in patients
Table 1 Baseline characteristics
Variable Appropriate initial therapy (n = 187) Inappropriate initial therapy (n = 72) P value
Age, yrs: 58.1 ± 17.6 62.0 ± 15.3 0.103
Male, n (%): 109 (58.3) 40 (55.6) 0.690
Race, n (%):
Caucasian 86 (46.0) 31 (43.1) 0.779
African-American 98 (52.4) 40 (55.6)
Other 3 (1.6) 1 (1.4)
CURB65 1.9 ± 1.4 2.1 ± 1.2 0.348
Charlson comorbidity score 4.5 ± 3.3 5.4 ± 1.2 0.090
Coexisting conditions, n (%):
Coronary artery disease 34 (18.2) 14 (19.4) 0.815
Congestive heart failure 56 (29.9) 31 (43.1) 0.045
Peripheral vascular disease 13 (7.0) 13 (18.1) 0.008
Cerebral vascular accident 18 (9.6) 10 (13.9) 0.322
Dementia 4 (2.1) 0 (0.0) 0.578
Chronic obstructive pulmonary disease 93 (49.7) 48 (66.7) 0.014
Cirrhosis 23 (12.3) 6 (8.3) 0.364
Diabetes 57 (30.5) 24 (33.3) 0.657
Chronic kidney disease 20 (10.7) 16 (22.2) 0.016
Underlying malignancy 32 (17.1) 12 (16.7) 0.932
HIV positive 1 (0.5) 0 (0.0) 1.000
Healthcare-associated risk factors, n (%):
Hospitalized in preceding 90 days 36 (19.3) 22 (30.6) 0.051
Long-term care resident 2 (1.1) 7 (9.7) 0.002
Chronic hemodialysis 3 (1.6) 6 (8.3) 0.016
Immunocompromised 38 (20.3) 17 (23.6) 0.562
Previous antibiotics 43 (23.0) 28 (38.9) 0.010
Number of healthcare risk factors: 0.7 ± 0.9 1.1 ± 1.0 <0.001
Healthcare-associated infection: 79 (42.2) 50 (69.4) <0.001
ICU admission, n (%): 52 (27.8) 29 (40.3) 0.052
Respiratory failure, n (%):
None 142 (75.9) 51 (70.8) 0.630
Intubation/mechanical ventilation 39 (20.9) 19 (26.4)
Mask ventilation 6 (3.2) 2 (2.8)
Hypotension, n (%): 110 (58.8) 45 (62.5) 0.589
Values are expressed as mean ± SD. CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate of 30 breaths per minute or greater, blood
pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older; HIV = human immunodeficiency virus; ICU = intensive care unit.
The Charlson comorbidity score predicts the ten-year mortality for a patient who may have a range of comorbid conditions, such as heart disease, AIDS, or cancer
(a total of 22 conditions).
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presenting to the hospital with pneumonia having HCAP
risk factors [9,13,14].
The importance of initial antibiotic therapy in patients
admitted to the hospital with pneumonia is suggested by
a recent medico-economic analysis conducted by Oster
et al. [21]. These investigators attempted to identify risk
factors for initial treatment failure in patients with CAP
in non-ICU settings, and to characterize the association
between initial treatment failure and length of stay,
total hospital charges, and mortality. Treatment failure
was associated with higher case fatality (8.5% vs. 3.3%),
longer hospital stays (mean [SD], 10.1 [8.1] days vs.
4.9 [3.3] days), and higher total hospital charges
($37,602 [$71,876] vs. $14,371 [$21,633]) (all compari-
sons, p < 0.01). An important limitation of their study is
that the role of inappropriate initial antibiotic treatment
was not examined.
The findings from our study also confirm the recent
observation made by Shorr et al. that patients with
pneumonia and healthcare-associated risk factors are
more likely to require 30-day hospital readmission
compared to pneumonia patients without healthcare-
associated risk factors [22]. Shorr and coworkers found
that admission from a long-term care residency, prior
antibiotic administration, recent hospitalization, and
immunosuppression were independent predictors for
30-day readmission. However, our study is unique in
focusing on patients diagnosed and treated for pre-
sumed CAP in the ED and linking 30-day hospital
readmission to the administration of inappropriate
Table 2 Infection characteristics
Variable Appropriate initial therapy (n = 187) Inappropriate initial therapy (n = 72) P value
Cultures source, n(%):
Blood only 46 (24.6) 13 (18.1) 0.041
BAL 5 (2.7) 6 (8.3)
Sputum 105 (56.1) 34 (47.2)
Tracheal aspirate 31 (16.6) 19 (26.4)
Achromobacter species 0 (0.0) 1 (1.4) 0.278
Acinetobacter species 1 (0.5) 5 (6.9) 0.007
Citrobacter species 1 (0.5) 0 (0.0) 1.000
Enterobacter species 1 (0.5) 6 (8.3) 0.002
Escherichia coli 11 (5.9) 0 (0.0) 0.038
Haemophilus influenzae 36 (19.3) 3 (4.2) 0.002
Klebsiella pneumoniae 7 (3.7) 1 (1.4) 0.450
Legionella species 1 (0.5) 0 (0.0) 1.000
Methicillin-resistant Staphylococcus aureus 0 (0.0) 34 (47.2) <0.001
Methicillin-susceptible Staphylococcus aureus 36 (19.3) 2 (2.8) <0.001
Moraxella catarrhalis 5 (2.7) 0 (0.0) 0.326
Proteus species 1 (0.5) 1 (1.4) 0.479
Pseudomonas aeruginosa 0 (0.0) 20 (27.8) <0.001
Streptococcus pneumoniae 79 (42.2) 3 (4.2) <0.001
Other Streptococci species 22 (11.8) 3 (4.2) 0.097
Polymicrobial, n (%): 14 (7.5) 5 (6.9) 0.881
Positive blood culture, n (%): 51 (27.3) 17 (23.6) 0.549
BAL bronchoalveolar lavage.
Table 3 Outcomes
Outcome Appropriate initial therapy (n = 187) Inappropriate initial therapy (n = 72) P value
Hospital mortality, n (%): 13 (7.0) 6 (8.3) 0.702
Hospital length of stay, days*: 7.0 ± 8.9 10.3 ± 12.0 0.017
4.0 [3.0,8.0] 6.95 [4.0,12.45]
30-day hospital readmission, n(%): 23 (12.3) 17 (23.6) 0.024
*Data expressed as mean ± SD and median with 25th and 75th percentiles.
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antibiotic treatment, which in turn was independently
associated with prior antibiotic exposure. Prior anti-
biotic exposure has been shown to be an important
risk factor for the development of certain types of
pneumonia to include drug-resistant Streptococcus
pneumoniae [23], ventilator-associated pneumonia [24]
and HCAP [13]. The common link among these types
of pneumonia is infection due to antibiotic-resistant
bacteria. The presence of a nexus between physician-
prescribed antibiotic therapy (e.g., prior antibiotic
exposure, inappropriate antibiotic treatment) and hos-
pital readmission underscores that modifiable patient
characteristics may play a role as key determinants of
whether a hospitalized patient with pneumonia eventu-
ally requires readmission.
There are several important limitations of our study
that should be noted. First, the study was performed at
an academic medical center and the results may not be
generalizable to other institutions, especially those with
a lower incidence of MDR pathogens. The large propor-
tion of pneumonia patients with HCAP risk factors
receiving broad-spectrum antibiotic therapy at our insti-
tution underscores this point. However, our findings are
in agreement with those from other investigators sup-
porting their overall validity [9-16,20]. Second, we did
not examine all aspects of medical care that may have
influenced the prescription of inappropriate therapy and
the outcomes of our patient cohort. For example, lack of
physician experience or knowledge regarding the im-
portance of broader empiric antibiotic coverage for pa-
tients with pneumonia and healthcare-associated risk
factors could have contributed to our results [25]. Third,
the retrospective nature of this study limits our ability to
infer causality between the identified risk factors and
inappropriate antibiotic therapy. Fourth, we did not
identify the specific causes or indications for the 30-day
readmissions. It is possible that the cause of readmission
in many cases may not have been related to the prior
episode of pneumonia or inappropriate treatment of the
pneumonia. Our analysis found that the presence of
peripheral vascular disease, greater CURB-65 scores, and
prior antibiotic exposure predispose to readmission.
These could all be considered to be markers of greater
co-morbidities or severity of illness accounting for the
readmissions.
Another important limitation of our study is that not
all healthcare-associated risk factors carry the same im-
portance. A US study found recent hospitalization, resi-
dency in a long-term care facility, chronic hemodialysis,
and admission to the ICU to be the best predictors of
pneumonia due to an antibiotic-resistant pathogen [26].
These findings are similar to those from a European
study that identified prior hospitalization, residence in a
long-term care setting, and chronic renal failure as pre-
dictors of antibiotic resistance in pneumonia [27]. How-
ever, a study from South Korea found prior antibiotic
exposure and recent hospitalization to be independent
predictors for antibiotic resistance [28]. Similarly, not all
investigators have found antibiotic resistance and in-
appropriate therapy to be problematic in patients with
pneumonia and healthcare-associated risk factors [29,30].
Several recent studies suggest adverse outcomes with
broader spectrum therapy of pneumonia [31,32]. This has
resulted in a call to avoid the use of the term HCAP and
instead to refer to certain patients with pneumonia as be-
ing at increased risk for antibiotic-resistance due to their
specific risk profile [33]. Moreover, it is important to ac-
knowledge that our study only included culture-positive
Table 4 Multivariate analyses of independent risk factors for inappropriate initial antibiotic treatment*
Variable Adjusted odds ratio 95% CI P value
Long-term care resident 9.05 3.93 – 20.84 0.008
Antibiotic exposure in previous 30 days 1.85 1.35 – 2.52 0.049
COPD 2.05 1.52 – 2.78 0.018
*Other covariates not in the table had a p value >0.05 including previous hospitalization, mechanical ventilation or mask ventilation, CURB65 score, Charlson
score, congestive heart failure, peripheral vascular disease, chronic kidney disease, hemodialysis, and ICU admission (Hosmer-Lemeshow goodness-of-fit test,
p = 0.726). ICU = intensive care unit; COPD = chronic obstructive pulmonary disease, CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate
of 30 breaths per minute or greater, blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older.
Table 5 Multivariate analyses of independent risk factors for 30-day hospital readmission*
Variable Adjusted odds ratio 95% CI P value
Antibiotic exposure in previous 30 days 2.12 1.45 – 3.10 0.047
Peripheral vascular disease 3.64 2.27 – 5.84 0.006
CURB 65 (1-point increments) 1.46 1.27 – 1.68 0.007
*Other covariates not in the table had a p value >0.05 including inappropriate initial antibiotic treatment, age, chronic dialysis, intensive care unit admission,
COPD, congestive heart failure, and the Charlson score (Hosmer-Lemeshow goodness-of-fit test, p = 0.431). ICU = intensive care unit; COPD = chronic obstructive
pulmonary disease, CURB65 = confusion of new onset, urea greater than 7 mmol/l, respiratory rate of 30 breaths per minute or greater, blood pressure less than
90 mmHg systolic or diastolic blood pressure 60 mmHg or less, age 65 or older.
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patients. Therefore, our data represent the more severe
end of the CAP/HCAP spectrum. The use of empiric
HCAP regimens do not appear to be justified in culture-
negative patients with less severe disease [34].
Conclusions
In conclusion we found that inappropriate therapy for
patients diagnosed and treated for CAP in the ED setting
is relatively common. Patients receiving inappropriate
therapy were significantly more likely to have HCAP
risk factors compared to patients receiving appropriate
therapy, suggesting that the identification of these risk
factors, or recognition of their clinical importance, was
underappreciated in these individuals. The association of
inappropriate therapy with longer hospital lengths of
stay and greater 30-day hospital readmission suggests
that efforts to reduce inappropriate therapy in the ED
would be beneficial. Several investigations have applied
multi-disciplinary approaches to the management of such
patients demonstrating improvements in antibiotic pre-
scription to include more targeted use of antimicrobial
agents [35,36]. Future studies evaluating rapid microbio-
logic techniques, informatics systems for the timely identifi-
cation of prior antibiotic exposure, and utility of new
antimicrobial agents are needed to improve the treatment
strategies for patients with pneumonia [37]. In the interim,
clinician identification of risk factors for antimicrobial re-
sistance should be emphasized in patients presenting to the
hospital with pneumonia in order to optimize the balance
between providing appropriate therapy and avoiding un-
necessary antibiotic exposure [38].
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